How is peripheral spondyloarthritis treated?

Updated: Feb 02, 2021
  • Author: Lawrence H Brent, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Pharmacologic treatment for peripheral spondyloarthritis includes the following:

  • Nonsteroidal anti-inflammatory drugs
  • Corticosteroid injections
  • Sulfasalazine
  • TNFi (infliximab, etanercept, adalimumab, certolizumab, golimumab)
  • IL-17i (secukinumab, ixekizumab)

In a study of adult patients with recent-onset peripheral spondyloarthritis (symptom duration < 12 weeks), early use of the TNFi golimumab resulted in sustained clinical remission in 49 of 60 patients (82%). Most patients (n=30) fulfilled criteria for sustained clinical remission by week 24. On follow-up at least 18 months after drug withdrawal, 26 of the 49 patients (53%) were still in drug-free remission. [102, 103] Similar data have been seen with all the TNFi and IL-17i.  IL-12/23i are effective in the peripheral arthritis and enthesitis of PsA but do not seem to be effective in axial disease such as is seen in AS.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!